

Anti-mouse LYVE-1

Description: Produced from sera of rabbits immunised with highly pure recombinant mouse soluble LYVE-1 produced in insect cells. The recombinant soluble LYVE-1 consists of amino acid 24 (Ala) to 228 (Gly) and is fused to a C-terminal His-tag (6xHis).

LYVE-1 has been identified as a major receptor for HA (extracellular matrix glycosaminoglycan hyaluronan) on the lymph vessel wall. The deduced amino acid sequence of LYVE-1 predicts a 322-residue type I integral membrane polypeptide 41% similar to the CD44 HA receptor with a 212-residue extracellular domain containing a single Link module the prototypic HA binding domain of the Link protein superfamily. Like CD44, the LYVE-1 molecule binds both soluble and immobilized HA. However, unlike CD44, the LYVE-1 molecule colocalizes with HA on the luminal face of the lymph vessel wall and is completely absent from blood vessels. Hence, LYVE-1 is the first lymph-specific HA receptor to be characterized and is a uniquely powerful marker for lymph vessels themselves.

Host species: Rabbits

Antigen: Recombinant mouse soluble Lyve-1

Purification: Protein-A Chromatography (+his tag depleted)

Stabilizer: none

Buffer: lyophilized from PBS, pH 7.4 w/o preservative

Formulation: lyophilized rabbit IgG

Reconstitution: The lyophilized IgG is stable at 4°C. for at least one month and for greater than a year when kept at -20°C. When reconstituted in sterile water/PBS to a concentration of >0.5 mg/ml the antibody is stable for at least six weeks at 2-4°C. Avoid repeated freeze-thaw cycles.

Applications

ELISA: Use at 1-15 µg/ml.

Western Analysis: Use at a concentration of 1-2 µg/ml with the appropriate secondary reagents.

FACS analysis: Use at 3-20 $\mu\text{g/ml}$ together with the appropriate secondary reagents

Immunohistochemistry: Not determined so far! Under work!

Optimal dilutions should be determined by each laboratory for each application.

Usage: Anti-mouse Lyve-1 is offered for research use. Not for drug use. Not for human use.

Catalogue number: 103-PA50S Size: 100 µg

Literature: [Carriera et al., Cancer Res 61:8079, 2001; Jackson DG Trends Cardiovasc Med 13:1, 2003; Sleeman et al., Microsc Res Tech 55:61, 2001; Mäkinen et al., EMBO J 20: 4762, 2001]

** please note : always centrifuge vials before opening **